Verquvo 5 mg (Vericiguat)
Verquvo 5 mg contains vericiguat, an oral soluble guanylate cyclase (sGC) stimulator indicated to reduce the risk of cardiovascular death and heart-failure (HF) hospitalization in adults with symptomatic chronic heart failure with reduced ejection fraction (HFrEF) who have had a recent decompensation event (hospitalization for HF or need for outpatient IV diuretics).
Verquvo is prescription-only and should be started and monitored by a cardiologist or clinician experienced in heart-failure management. Patient selection and concomitant guideline-directed medical therapy should be reviewed before initiation.
Product introduction
Vericiguat stimulates soluble guanylate cyclase, increasing cyclic GMP and thereby improving vascular and myocardial function in failing hearts. It is provided as 2.5 mg, 5 mg and 10 mg oral tablets; the 5 mg tablet is commonly used during the up-titration phase or for patients whose dose has been adjusted.
Uses of Verquvo 5 mg (Vericiguat)
Indicated use (specialist-directed):
- Reduction of risk of cardiovascular death or heart-failure hospitalization in adults with symptomatic chronic HFrEF (LVEF <45%) following recent HF decompensation requiring hospitalisation or outpatient IV diuretics.
- Used as an add-on to guideline-directed medical therapy for appropriate high-risk patients.
Note: Vericiguat is not indicated for all heart-failure patients — suitability should be determined by your specialist.
Benefits of Verquvo 5 mg (Vericiguat)
- Proven to reduce HF events: in the VICTORIA trial vericiguat reduced the composite endpoint of cardiovascular death or HF hospitalization in a high-risk HFrEF population.
- Oral, once-daily dosing: convenient addition to existing oral HF regimens.
- Novel mechanism: sGC stimulation targets the NO–sGC–cGMP pathway, which is impaired in HF.
Side effects of Verquvo 5 mg (Vericiguat)
Common and important adverse effects:
- Hypotension and symptomatic low blood pressure (dizziness, lightheadedness).
- Anaemia (decrease in haemoglobin observed in trials).
- Headache, nausea, and fatigue in some patients.
Serious risks: symptomatic hypotension and clinically significant anaemia — monitor blood pressure and haemoglobin during therapy and report dizziness, syncope, unusual tiredness or signs of bleeding.
How to use Verquvo 5 mg (Vericiguat)
- Start at 2.5 mg orally once daily with food, and double the dose approximately every 2 weeks as tolerated to 5 mg once daily and then to the target maintenance dose of 10 mg once daily. The 5 mg tablet is the intermediate step during up-titration. Do not exceed the recommended titration schedule unless instructed by your specialist.
- Take with food to improve absorption.
- If a dose is missed, take it as soon as remembered on the same day; do not double doses. Follow your prescriber’s instructions for interruptions.
- Ensure concomitant guideline-directed therapy (ACEi/ARB/ARNI, beta-blocker, MRA, SGLT2 inhibitor) is optimised where appropriate before and during treatment — vericiguat is additive to background HF treatment.
How Verquvo works
Vericiguat stimulates soluble guanylate cyclase (sGC), enhancing generation of cyclic GMP (cGMP) in the NO–sGC–cGMP signalling pathway. Increased cGMP promotes vasodilation and favourable myocardial and vascular effects that can reduce HF progression and events.
Safety advice
| Pregnancy / Breastfeeding | Vericiguat can cause embryo-foetal harm. Women capable of becoming pregnant must have a negative pregnancy test before starting and must use effective contraception during treatment and for 1 month after the final dose. Avoid breastfeeding during treatment. |
| Blood pressure | Do not start vericiguat in patients with symptomatic hypotension or systolic blood pressure (SBP) <100 mmHg. Monitor BP regularly — caution when initiating or up-titrating therapy. |
| Anaemia | Monitor haemoglobin prior to and during therapy; consider withholding or reducing dose if clinically significant anaemia occurs. |
| Drug interactions | Concomitant use with other vasodilators or nitrates may increase risk of hypotension — review all medications. Strong inducers of UDP-glucuronosyltransferases (UGTs) may reduce vericiguat exposure. Discuss all medicines and supplements with your clinician. |
| Renal / Hepatic impairment | No dose adjustment required for mild–moderate renal impairment; limited data in severe renal or hepatic impairment — specialist guidance required. Check local product information. |
What if you forget to take Verquvo?
- If you miss a dose, take it the same day if you remember, otherwise skip and take the next scheduled dose — do not double doses. Follow your prescriber’s specific instructions for missed doses or interruptions.
All substitutes
Therapies for HFrEF are selected based on guideline-directed care and patient profile. Alternatives and complementary treatments include optimisation of ACEi/ARB/ARNI, beta-blockers, MRAs, SGLT2 inhibitors, diuretics, device therapy and advanced HF interventions where indicated. Vericiguat is an add-on for a selected high-risk subgroup.
Quick tips
- Take vericiguat with food at roughly the same time each day.
- Record BP (supine and seated/standing) during titration and report symptomatic hypotension promptly.
- Ensure pregnancy prevention measures where applicable and monitor haemoglobin periodically.
- Carry a treatment card noting vericiguat and emergency contacts for healthcare providers.
Fact Box
| Generic name | Vericiguat |
| Brand | Verquvo 5 mg |
| Drug class | Soluble guanylate cyclase (sGC) stimulator |
| Form | Oral tablet (2.5, 5, 10 mg available) |
| Typical dosing | Start 2.5 mg once daily with food; double every ~2 weeks to 5 mg then to target 10 mg once daily as tolerated (5 mg is the intermediate titration step). |
| Prescription | Required — cardiology/physician specialist |
Patient concerns
Will Verquvo cure my heart failure? No single drug cures HF. Verquvo can reduce the risk of HF hospitalization and cardiovascular death in selected high-risk patients when added to guideline care, but overall management includes multiple medications, lifestyle changes and sometimes device therapy. Discuss individual prognosis with your specialist.
How quickly will I notice effects? Benefits in event reduction were seen over trial follow-up; symptomatic changes may be subtle — vericiguat is primarily used to reduce clinical events rather than produce immediate symptom relief.
User feedback
Clinical trial patients described reduced HF events in the studied high-risk population; common tolerability issues included hypotension and anaemia that required monitoring. Real-world experience is expanding under specialist follow-up.
Are you currently taking Verquvo 5 mg? Let us know how it is working for you by taking this survey.
FAQs
Can I take Verquvo with nitrates or PDE5 inhibitors?
No. Combining vericiguat with nitrates or PDE5 inhibitors may increase the risk of symptomatic hypotension — avoid coadministration unless instructed by a specialist.
Is Verquvo safe in pregnancy?
No — vericiguat may cause fetal harm. Use effective contraception during treatment and for 1 month after stopping; do not breastfeed while on therapy.
How should I store Verquvo?
Store at controlled room temperature (per product label). Keep out of reach of children and do not use after the expiry date.
Related products
- Other HF medicines (ACEi/ARB/ARNI, beta-blocker, MRA, SGLT2 inhibitors)
- Diuretics and supportive HF therapies
- Device and advanced HF services
Want to share the information?
Share this article to help clinicians and patients understand vericiguat therapy and safe use.
Disclaimer:
This article is educational only and does not replace professional medical advice. Verquvo (vericiguat) must be prescribed and monitored by qualified clinicians. For specific guidance follow your treating cardiologist and the product label.
References
- FDA Prescribing Information — Verquvo (vericiguat) dosing, indications & warnings.
- Merck / trial & approval announcement (VICTORIA trial results).
- StatPearls / NCBI overview of vericiguat for HFrEF.
- EMA product information and safety advice.
Marketer details
genericurerx — support@genericurerx.com — www.genericurerx.com
In case of any issues, contact us
For ordering or prescription verification use live chat or our contact page. For medical concerns contact your treating cardiologist immediately.
Lab tests offered by us
- Haemoglobin / CBC monitoring
- Blood pressure monitoring during titration
- Renal function assessment as indicated
Additional offers
Prescription coordination, cardiology referrals and monitoring support available on request. Use code GLOBAL10 where eligible for first-order discounts.
Reviews
There are no reviews yet.